Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.7370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Angela E Alnemri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Cytokines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Biostatistics Shared Resource at the Sidney Kimmel Cancer Center - Jefferson Health.
Themen: Patientensicherheit
Abstract (Originalsprache)
Objectives
Certain low‐level immune‐related adverse events (irAEs) have been associated with survival benefits in patients with various solid tumors on immune checkpoint inhibitors (ICIs). We aimed to investigate the association between irAEs and response to neoadjuvant ICIs in patients with head and neck squamous cell carcinoma (HNSCC) and to identify differences in circulating cytokine levels based on irAE status.
Methods
This was a retrospective cohort study including three neoadjuvant clinical trials from July 2017 to January 2022: NCT03238365 (nivolumab ± tadalafil), NCT03854032 (nivolumab ± BMS986205), NCT03618654 (durvalumab ± metformin). The presence and type of irAEs, pathologic treatment response, and survival were compared. Canonical linear discriminant analysis (LDA) was performed to identify combinations of circulating cytokines predictive of irAEs using plasma sample multiplex assay.
Results
Of 113 participants meeting inclusion criteria, 32 (28.3%) developed irAEs during treatment or follow‐up. Positive p16 status was associated with irAEs (odds ratio [OR] 2.489; 95% CI 1.069–6.119; p = 0.043). irAEs were associated with pathologic treatment response (OR 3.73; 95% CI 1.34–10.35; p = 0.011) and with higher OS in the combined cohort (HR 0.319; 95% CI 0.113–0.906; p = 0.032). Patients with irAEs within the nivolumab cohort had significant elevations of select cytokines pre‐treatment. Canonical LDA identified key drivers of irAEs among all trials, which were highly predictive of future irAE status. Conclusions irAEs are associated with response to neoadjuvant ICI therapy in HNSCC and can serve as clinical indicators for improved clinical outcomes. irAEs can be predicted by concentrations of several circulating cytokines prior to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Biostatistics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Angela E Alnemri, Stacey Gargano
Förderung
- NCI NIH HHS
- Biostatistics Shared Resource at the Sidney Kimmel Cancer Center - Jefferson Health
Zitieren
APA
Alnemri, A. E., Tekumalla, S., Moroco, A. E., Vathiotis, I., Tuluc, M., Gargano, S., Zhan, T., Cognetti, D. M., Curry, J. M., Argiris, A., Linnenbach, A., South, A. P., Harshyne, L. A., Johnson, J. M., & Luginbuhl, A. J. (2024). Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.7370
Vancouver
Alnemri AE, Tekumalla S, Moroco AE, Vathiotis I, Tuluc M, Gargano S, et al. Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.7370
BibTeX
@article{Alnemri2024,
author = {Alnemri, Angela E and Tekumalla, Sruti and Moroco, Annie E and Vathiotis, Ioannis and Tuluc, Madalina and Gargano, Stacey and Zhan, Tingting and Cognetti, David M and Curry, Joseph M and Argiris, Athanassios and Linnenbach, Alban and South, Andrew P and Harshyne, Larry A and Johnson, Jennifer M and Luginbuhl, Adam J},
title = {Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7370}
}
EUVIMED